Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
A. Bhattacharya, Abhirup Chowdhury, Koel Chaudhury, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 1, pp. 188581-188581
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

The Multifaceted Biology of PCSK9
Nabil G. Seidah, Annik Prat
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 558-582
Open Access | Times Cited: 148
PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages
Lu Wang, Shuangshuang Li, Huanhua Luo, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 140
Functional significance of cholesterol metabolism in cancer: from threat to treatment
Mingming Xiao, Jin Xu, Wei Wang, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 9, pp. 1982-1995
Open Access | Times Cited: 77
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Xuhui Bao, Yongjun Liang, Hanman Chang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 59
PCSK9 Inhibition: From Current Advances to Evolving Future
Chunping Liu, Jing Chen, Huiqi Chen, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 2972-2972
Open Access | Times Cited: 63
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
Chi Chun Wong, Jian‐Lin Wu, Fenfen Ji, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study
Si Fang, James Yarmolinsky, Dipender Gill, et al.
PLoS Medicine (2023) Vol. 20, Iss. 1, pp. e1003988-e1003988
Open Access | Times Cited: 35
Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review
Stefan Zivkovic, Gorica Marić, Nataša Cvetinovic, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1517-1517
Open Access | Times Cited: 30
Targeting lipid metabolism in metastatic prostate cancer
Tahlia Scheinberg, Blossom Mak, Lisa M. Butler, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 24
The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting
Wenxin Wang, Wei Li, Dan Zhang, et al.
Genes (2024) Vol. 15, Iss. 1, pp. 132-132
Open Access | Times Cited: 11
Protein S-palmitoylation modification: implications in tumor and tumor immune microenvironment
Yijiao Chen, Yongsheng Li, Lei Wu
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities
Wen G. Jiang, Weilin Jin, Aman Xu
International Journal of Biological Sciences (2024) Vol. 20, Iss. 6, pp. 2044-2071
Open Access | Times Cited: 9
The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
Nabil G. Seidah
Journal of Lipid Research (2021) Vol. 62, pp. 100130-100130
Open Access | Times Cited: 55
Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor
Jia Gu, Neng Zhu, Hongfang Li, et al.
Cellular Oncology (2022) Vol. 45, Iss. 5, pp. 709-728
Closed Access | Times Cited: 33
The evolving landscape of PCSK9 inhibition in cancer
Palak P. Oza, Khosrow Kashfi
European Journal of Pharmacology (2023) Vol. 949, pp. 175721-175721
Open Access | Times Cited: 22
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Łukasz Wołowiec, Joanna Osiak, Anna Wołowiec, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 323-323
Open Access | Times Cited: 18
Drug development advances in human genetics‐based targets
X. Zhang, Wenjun Yu, Yan Li, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 8
Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer
Qi‐Chao Yang, Shuo Wang, Yuan‐Tong Liu, et al.
iScience (2023) Vol. 26, Iss. 6, pp. 106916-106916
Open Access | Times Cited: 14
The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy
Chou‐Yi Hsu, Mustafa Nasrat Abdulrahim, Mohammed Ahmed Mustafa, et al.
Medical Oncology (2024) Vol. 41, Iss. 8
Closed Access | Times Cited: 4
PCSK9 in metabolism and diseases
Amir Ajoolabady, Domenico Praticò, Mohsen Mazidi, et al.
Metabolism (2024) Vol. 163, pp. 156064-156064
Closed Access | Times Cited: 4
Prognostic implications of PCSK9 expression in HER2-positive breast cancer
Zongwen Wu, D. Wu, Chengsheng Huang, et al.
ONCOLOGIE (2025)
Closed Access
Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD‐1 Blockade in MSS Colorectal Cancer
Qi‐Long Wang, Zijie Chen, Xiaofei Lü, et al.
Advanced Science (2025)
Open Access
(−)-Oleuropein as a Novel Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence Suppressor via Targeting PCSK9-LDLR Axis
Nehal A. Ahmed, Mohamed M. Mohyeldin, Hassan Y. Ebrahim, et al.
Nutrients (2025) Vol. 17, Iss. 9, pp. 1445-1445
Open Access
Inhibition of PCSK9 with polypurine reverse hoogsteen hairpins: A novel gene therapy approach
Ester López-Aguilar, Silvia Cecilia Pacheco-Velázquez, Maria Antònia Busquets, et al.
Biochemical Pharmacology (2025), pp. 116976-116976
Open Access
PCSK9 is a passenger gene in head and neck cancer with minimal pathological influence
Hyunji Kim, Dong-Guk Park, Su‐Jung Choi, et al.
Archives of Oral Biology (2025), pp. 106302-106302
Closed Access
Page 1 - Next Page

Scroll to top